Alexis Ogdie-Beatty, MD
Rheumatology · Philadelphia, PANPI 1871657882
Payments from drug & device makers
Across 567 payments — averaging $10,019 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$2.9M
- Novartis$1.9M
- Pfizer$312K
- AbbVie$287K
- UCB SA$78K
- Eli Lilly$76K
- plus $164K from 16 others
Across 79 payments — averaging $1608.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$57K
- Pfizer$49K
- Novartis$18K
- AbbVie$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 12 | $2,912,591 |
| Novartis | 100 | $1,850,447 |
| Pfizer | 70 | $312,253 |
| AbbVie | 91 | $287,116 |
| UCB SA | 12 | $78,163 |
| Eli Lilly | 29 | $76,002 |
| UCB, Inc. | 12 | $33,749 |
| Janssen Scientific Affairs, LLC | 113 | $27,691 |
| E.r. Squibb & Sons, L.L.C. | 49 | $23,294 |
| Amgen | 11 | $20,935 |
| Lilly USA, LLC | 14 | $19,371 |
| Sun Pharmaceutical Industries Inc. | 3 | $11,250 |
| Bristol Myers Squibb | 4 | $8,986 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $4,023 |
| Janssen Global Services, LLC | 1 | $3,240 |
| GSK | 1 | $2,925 |
| Gilead | 1 | $2,500 |
| Johnson & Johnson | 1 | $2,300 |
| Sanofi | 15 | $2,042 |
| Genentech, Inc. | 15 | $817 |
| Genentech USA, Inc. | 7 | $729 |
| Assertio Therapeutics, Inc. | 2 | $335 |
How this compares
$5,680,761 in reported general payments places this provider in the 95th percentile of 351 rheumatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Philadelphia
- Jonathan MinerPhiladelphia$3.8M
- Alan EpsteinPhiladelphia$1.2M
- Fabian Mendoza BallesterosPhiladelphia$564K
- James UdellPhiladelphia$516K
- Nora SandorfiPhiladelphia$445K
- Michael GeorgePhiladelphia$367K
- Shubhasree BanerjeePhiladelphia$348K
- Chris DerkPhiladelphia$243K
- Bruce HoffmanPhiladelphia$141K
- Philip CohenPhiladelphia$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.